Eli Lilly and Co
Five stocks to acquire just before the year finish, according to the professionals
Quite a few shares have observed enormous rallies this year as buyers turned bullish on sectors like Big Tech, biotech, electric powered cars, and weight decline drugs. As the year-conclusion nears, CNBC Pro requested a few fund managers for sectors — and stocks — they are bullish on in the guide-up to 2024. In this […]
Read More
Eli Lilly vs. Novo Nordisk: The professionals supply their verdict on the viral body weight-reduction stocks
It has been really a calendar year for both Eli Lilly and Novo Nordisk given the increase in excess weight-reduction drugs. Stocks of both pharmaceutical corporations have rallied this 12 months. Shares in Eli Lilly are up all over 60% yr-to-date, while its Danish counterpart Novo Nordisk has noticed a achieve of about 50%. As […]
Read More
Eli Lilly weight loss drug Zepbound now available at pharmacies as rival Wegovy faces shortages
FDA approves Eli Lilly’s Zepbound, a weight loss drug similar to Ozempic and Wegovy Courtesy: Eli Lilly Eli Lilly on Tuesday said its recently approved weight loss treatment Zepbound is now available at pharmacies across the U.S., serving as an alternative to rival obesity drugs such as Wegovy that are facing supply issues. Zepbound is […]
Read More
December’s ‘best-in-class’ shares contain this weight problems beneficiary, Wall Road analysts say
An being overweight beneficiary and a snack foods company are just a several of the prime stocks to acquire in December, analysts reported this week. Wall Road investigate companies named a slew of corporations that they consider have upside heading into the years close. CNBC Pro combed by way of recent analyst notes to come […]
Read More
Pfizer’s twice-daily weight loss pill joins a long list of obesity drug flops
Sopa Images | Lightrocket | Getty Images Pfizer’s twice-daily version of its experimental weight loss pill has now joined a long list of other scrapped drugs that aimed to treat obesity but came with unintended consequences. The drugmaker on Friday said it will stop developing the twice-daily treatment, danuglipron, after obese patients taking the drug […]
Read More
Why Pfizer’s latest stumble in the obesity market is a boon for Eli Lilly
Pfizer (PFE) has suffered another setback in its efforts to develop a weight-loss pill — and that’s good news for Club holding Eli Lilly (LLY) as it looks to maintain an edge in the fast-growing obesity-treatment market. Pfizer said Friday it will discontinue its twice-daily weight-loss pill, danuglipron, after patients in a mid-stage trial experienced […]
Read More
Pfizer to discontinue twice-daily weight loss pill due to high rates of adverse side effects
Pfizer on Friday said it would stop developing the twice-daily version of its experimental weight loss pill after obese patients taking the drug lost weight but had trouble tolerating the drug in a mid-stage clinical study. The drugmaker observed high rates of adverse side effects, which were mostly mild and gastrointestinal, among patients. A significant […]
Read More
Novo Nordisk sues two pharmacies for allegedly selling tainted Wegovy, Ozempic knockoffs
A 0.25 mg injection pen of Novo Nordisk’s weight-loss drug Wegovy is shown in this photo illustration in Oslo, Norway, August 31, 2023. Victoria Klesty | Reuters Novo Nordisk on Thursday said it sued two compounding pharmacies in Florida for allegedly selling impure and “potentially unsafe” drugs claiming to contain semaglutide, the active ingredient in […]
Read More
Mounjaro is more effective than Ozempic for weight loss in overweight and obese adults, real world study says
A pharmacist displays a box of Mounjaro, a tirzepatide injection drug used for treating type 2 diabetes and made by Lilly at Rock Canyon Pharmacy in Provo, Utah, May 29, 2023. George Frey | Reuters The blockbuster diabetes drug Mounjaro is more effective for weight loss than another highly popular treatment, Ozempic, in overweight or […]
Read More
Health care, AI and far more: How a single professional is investing for a ‘Goldilocks’ economic climate
Uncertainty in world-wide marketplaces coupled with persistently superior inflation has elevated the problem no matter whether there will be a tricky or a soft economic landing. Andy Budden, financial commitment director for equities at international monetary services agency Money Team, is in the latter camp and expects the U.S. Federal Reserve to maintain fees high […]
Read More